American Society of Hematology

Figure 4.

$BT with a focal RT field in a CAR T-cell patient. Scout (A) and axial (D) images of a PET-CT scan in a male patient with primary refractory DLBCL who presented with cauda equina syndrome and a sacral mass. Emergent RT was administered with a 3-dimensional conformal RT plan that was transitioned to a volumetric-modulated arc therapy plan to a total dose of ∼43 Gy administered in 2.5-Gy fractions; the PET avid left gluteal mass (white arrow) was excluded from the RT field in an effort to limit bone marrow dose (E). The initial response assessment at day 30 revealed CR to therapy with a score of 2 on a 5-point scale (B,F). The 3-month post–axi-cel PET-CT scan revealed recurrent disease in the left gluteal region that was positive before axi-cel therapy but excluded from the RT field (C,G).$

BT with a focal RT field in a CAR T-cell patient. Scout (A) and axial (D) images of a PET-CT scan in a male patient with primary refractory DLBCL who presented with cauda equina syndrome and a sacral mass. Emergent RT was administered with a 3-dimensional conformal RT plan that was transitioned to a volumetric-modulated arc therapy plan to a total dose of ∼43 Gy administered in 2.5-Gy fractions; the PET avid left gluteal mass (white arrow) was excluded from the RT field in an effort to limit bone marrow dose (E). The initial response assessment at day 30 revealed CR to therapy with a score of 2 on a 5-point scale (B,F). The 3-month post–axi-cel PET-CT scan revealed recurrent disease in the left gluteal region that was positive before axi-cel therapy but excluded from the RT field (C,G).

This Feature Is Available To Subscribers Only